Advertisement
Screener

Vor Biopharma Inc. (VOR) Cash Flow Breakdown

2.8 / 5 stars · 68/120 Roast Me

Vor Biopharma Inc. Cash Flow Breakdown

Cash flow breakdown shows where Vor Biopharma Inc.'s cash came from and where it went: from running the business, from investing (buying or selling equipment, companies and investments) and from financing (borrowing, paying back loans, buying back shares, paying dividends). One row per year or quarter. A minus sign means cash went out. Financing is shown line by line: buybacks, dividends, debt paid back, new debt and the rest. All amounts are the filed figures for that period.

  • Fiscal year ended 2025-12-31: from running the business, $142.71M went out.
  • Fiscal year ended 2025-12-31: from investing, $48.80M went out.
  • Fiscal year ended 2025-12-31: from financing, $503.81M came in.
  • Fiscal year ended 2025-12-31: change in cash, $312.29M came in.

A minus sign means cash went out. * = worked out from the filed year-to-date figures (hover to see how); greyed = already counted inside another line.

Each year (12 month)

Fiscal year endRunning the businessFrom investingDividendsStaff share taxNew shares soldNot split outChange in cash
2025-12-31-$142.71M-$48.80M$0.00-$254.00K$70.11M$433.95M*$312.29M
2024-12-31-$99.66M$96.86M$0.00-$333.00K$275.00K$53.45M*$50.59M
2023-12-31-$100.29M$71.01M$0.00-$1.19M$4.58M-$26.35M
2022-12-31-$85.14M-$94.09M$0.00$4.45M$112.69M*-$62.09M
2021-12-31-$69.14M-$91.65M$0.00$553.00K$232.36M*$72.12M
2020-12-31-$36.29M-$4.16M$0.00$259.00K$82.27M*$42.07M

Each quarter (3 month)

Quarter endRunning the businessFrom investingStaff share taxNew shares soldNot split outChange in cash
2026-06-30-$25.38M*-$36.53M*-$2.00K*
2026-03-31-$38.25M-$263.24M-$2.00K$74.87M*-$226.61M
2025-12-31-$22.80M*-$48.97M*-$148.00K*$49.85M*$258.10M*
2025-09-30-$53.66M*-$244.00K*-$19.00K*$20.26M*$1.31M*
2025-06-30-$35.18M*$646.00K*-$32.00K*$0.00*$175.10M*
2025-03-31-$31.07M-$230.00K-$55.00K$0.00-$551.00K*-$31.90M
2024-12-31-$24.06M*-$72.00K*-$30.00K*-$22.00K*$53.34M*
2024-09-30-$23.29M*-$34.00K*-$70.00K*$111.00K*
2024-06-30-$21.85M*$52.99M*-$51.00K*-$92.00K*
2024-03-31-$30.46M$43.97M-$182.00K$278.00K$13.60M
2023-12-31-$24.03M*$10.34M*-$22.00K*-$15.00K*
2023-09-30-$27.90M*$40.54M*-$220.00K*$392.00K*
2023-06-30-$24.10M*$13.64M*-$545.00K*$579.00K*
2023-03-31-$24.27M$6.50M-$400.00K$3.62M-$703.00K*-$15.25M
2022-12-31-$18.35M*-$97.04M*$106.00K*$112.16M*
2022-09-30-$18.90M*$12.70M*$3.84M*
2022-06-30-$24.99M*-$2.70M*$100.00K*$504.00K*
2022-03-31-$22.90M-$7.05M$200.00K-$29.76M
2021-12-31-$17.59M*-$5.95M*$308.00K*
2021-09-30-$17.34M*-$8.49M*$201.00K*
2021-06-30-$16.57M*-$76.04M*$26.00K*
2021-03-31-$17.65M-$1.17M$18.00K$232.83M*$214.03M
2020-12-31-$13.63M*-$1.48M*$46.00K*
2020-09-30-$8.24M*-$1.59M*$153.00K*
2020-06-30-$8.33M*-$552.00K*$17.00K*$64.17M*
2020-03-31-$6.08M-$545.00K$43.00K$17.72M*$11.13M

Similar stocks

Stock NameCountryMarket CapPE Ratio
MeiraGTx Holdings plc (MGTX)United States$1.061B16.10
Monte Rosa Therapeutics, Inc. (GLUE)United States$1.002B-12.81
Replimune Group, Inc. (REPL)United States$1.186B-3.13
Cullinan Therapeutics, Inc. (CGEM)United States$0.993B-5.72
Odyssey Therapeutics, Inc. (ODTX)United States$0.960B
Sana Biotechnology, Inc. (SANA)United States$0.886B-4.92
Candel Therapeutics, Inc. (CADL)United States$0.885B-8.86
Attovia Therapeutics, Inc. (ATTO)United States$0.828B
Solid Biosciences Inc. (SLDB)United States$0.802B-5.07
4D Molecular Therapeutics, Inc. (FDMT)United States$0.733B-4.10